Fimepinostat in Treating Brain Tumors in Children and Young Adults
Public ClinicalTrials.gov record NCT03893487. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Target Validation Study of Fimepinostat in Children and Young Adults With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, or Recurrent High-Grade Glioma (HGG)
Study identification
- NCT ID
- NCT03893487
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Early Phase 1
- Lead sponsor
- Sabine Mueller, MD, PhD
- Other
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Interventions
- Fimepinostat Drug
- Therapeutic Conventional Surgery Procedure
Drug · Procedure
Eligibility (public fields only)
- Age range
- 3 Years to 39 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 6, 2019
- Primary completion
- Oct 30, 2022
- Completion
- Aug 30, 2027
- Last update posted
- Jul 10, 2025
2019 – 2027
United States locations
- U.S. sites
- 18
- U.S. states
- 16
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Children's Hospital Los Angeles (CHLA) | Los Angeles | California | 90027 | — |
| Rady Children's Hospital | San Diego | California | 92123 | — |
| University of California, San Francisco | San Francisco | California | 94143 | — |
| Children's National Medical Center | Washington D.C. | District of Columbia | 20010 | — |
| University of Florida | Gainesville | Florida | 32611 | — |
| Lurie Children's Hospital of Chicago | Chicago | Illinois | 60611 | — |
| Johns Hopkins Hospital | Baltimore | Maryland | 21231 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| University of Michigan Hospital | Ann Arbor | Michigan | 48109 | — |
| Children's Minnesota Research Institute | Minneapolis | Minnesota | 55404 | — |
| Washington University in St Louis | St Louis | Missouri | 63110 | — |
| Nationwide Children's | Columbus | Ohio | 43205 | — |
| Oregon Health and Science University | Portland | Oregon | 97239 | — |
| Children's Hospital of Philadelphia (CHOP) | Philadelphia | Pennsylvania | 19146 | — |
| St. Jude Children's Research Hospital | Memphis | Tennessee | 38105 | — |
| Texas Children's Hospital | Houston | Texas | 77030 | — |
| University of Utah, Children's Primary | Salt Lake City | Utah | 84113 | — |
| Seattle Children's Hospital | Seattle | Washington | 98105 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03893487, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 10, 2025 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03893487 live on ClinicalTrials.gov.